Health-related quality of life in boys with constitutional delay of growth and puberty.
16D
constitutional delay of growth and puberty
delayed puberty
health-related quality of life
letrozole
testosterone
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
08
2022
accepted:
10
11
2022
entrez:
15
12
2022
pubmed:
16
12
2022
medline:
17
12
2022
Statut:
epublish
Résumé
Constitutional delay of growth and puberty (CDGP) is the most common reason for delayed puberty in healthy male adolescents. The main indication for medical treatment for this condition is psychosocial burden. However, to the best of our knowledge, no previous study has addressed the impact of puberty-promoting treatment on health-related quality of life (HRQoL) among boys with CDGP. We investigated HRQoL in 22 boys with CDGP, who participated in a randomized controlled trial in four Finnish pediatric endocrinology outpatient clinics between 2013 and 2017. The boys were randomized to receive either aromatase inhibitor letrozole (2.5mg/day; n=11) or intramuscular testosterone (1mg/kg/every 4 weeks; n=11) for 6 months and followed up to 12 months. HRQoL was assessed with a generic self-assessment 16D At baseline, the mean 16D score of the CDGP boys was similar to the age-matched reference population (0.95 vs 0.96, p=0.838). However, the physical appearance score (satisfaction with general appearance, height and weight) was significantly lower in the CDGP boys (0.75 vs 0.92, p=0.004) than their peers. Twelve months after treatment, Appearance had improved significantly (0.75 vs 0.87, p=0.004) and no HRQoL dimension was inferior compared to the age-matched reference population. In terms of HRQoL, the main impact of delayed puberty was dissatisfaction with physical appearance. Puberty promoting therapy was associated with a positive change in perceived appearance, with no clear difference between low-dose testosterone and letrozole treatments.
Identifiants
pubmed: 36518253
doi: 10.3389/fendo.2022.1028828
pmc: PMC9743641
doi:
Substances chimiques
Letrozole
7LKK855W8I
Testosterone
3XMK78S47O
Banques de données
ClinicalTrials.gov
['NCT01797718']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1028828Informations de copyright
Copyright © 2022 Kariola, Varimo, Huopio, Tenhola, Voutilainen, Kosola, Toppari, Sintonen, Miettinen, Raivio and Hero.
Déclaration de conflit d'intérêts
HS is one of the developers of the 16D. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Références
J Am Acad Child Adolesc Psychiatry. 2004 Jun;43(6):718-26
pubmed: 15167088
Congenit Heart Dis. 2018 May;13(3):463-469
pubmed: 29521004
J Youth Adolesc. 1990 Feb;19(1):33-41
pubmed: 24272234
Clin Endocrinol (Oxf). 2017 Jan;86(1):75-87
pubmed: 27467188
Pediatr Clin North Am. 1980 Feb;27(1):71-7
pubmed: 6966388
Child Adolesc Psychiatry Ment Health. 2019 Mar 26;13:17
pubmed: 30962819
Int J Pediatr Otorhinolaryngol. 2014 Sep;78(9):1508-12
pubmed: 25023455
Hum Reprod. 2017 Jan;32(1):147-153
pubmed: 27927844
Clin Endocrinol (Oxf). 2015 Jul;83(1):141-3
pubmed: 25515567
Qual Life Res. 1996 Apr;5(2):205-11
pubmed: 8998489
Dev Psychol. 2019 Jul;55(7):1566-1578
pubmed: 30985163
Arch Dis Child. 1990 Oct;65(10):1109-12
pubmed: 2248500
Child Dev. 2001 Sep-Oct;72(5):1439-50
pubmed: 11699680
Neuromuscul Disord. 2021 Dec;31(12):1259-1265
pubmed: 34702655
Acta Otolaryngol. 2018 Jul;138(7):652-658
pubmed: 29468919
Pediatrics. 1982 Jun;69(6):681-7
pubmed: 7043385
J Clin Endocrinol Metab. 2002 Apr;87(4):1613-20
pubmed: 11932291
Psychol Bull. 2017 Mar;143(3):293-320
pubmed: 27893220
Lancet Child Adolesc Health. 2019 Feb;3(2):109-120
pubmed: 30612946
J Pediatr. 1982 Sep;101(3):477-80
pubmed: 7108676
Horm Res Paediatr. 2018;89(3):184-188
pubmed: 29502117
N Engl J Med. 2012 Feb 2;366(5):443-53
pubmed: 22296078
J Paediatr Child Health. 2011 Nov;47(11):832-7
pubmed: 21435075
Dev Psychopathol. 2015 Nov;27(4 Pt 1):1331-40
pubmed: 26439078
Qual Life Res. 2015 Mar;24(3):599-606
pubmed: 25145637
J Adolesc Health. 1999 Aug;25(2):155-65
pubmed: 10447043
Dev Psychopathol. 2009 Spring;21(2):593-620
pubmed: 19338700
Ann Med. 2001 Jul;33(5):328-36
pubmed: 11491191